When should you hire a FTE, engage a consultant, or use a CRO? Choosing the right staffing model can make or break your R&D efforts. In our new report, our decision tree questionnaire helps you design the optimal team tailored to your needs. Learn how to balance cost, agility, and control with our expert guidance and get started on your path to better development outcomes. Access the report here: https://ow.ly/TS6E50Sxnmp #Clora #biotech #pharma #hiring #lifesciences #consultants #whitepaper
Clora
Technology, Information and Internet
Boston, Massachusetts 4,635 followers
The best place to discover, build, and manage on-demand life science teams.
About us
Clora is an intelligent platform that matches life science companies with flexible, on-demand expertise. Clora is faster, more cost-efficient, and yields higher quality on-demand talent compared to traditional recruitment methods. Clora has access to the entire global network of life science consultants, with decades of combined industry experience across dozens of roles from companies like Merck, Johnson & Johnson, Pfizer, Novartis, and the FDA. Clora was built by industry veterans who have experienced firsthand the pain and costs associated with staffing projects with the right talent. With Clora, you simply post a project, identifying your unique requirements and our proprietary technology will select up to 3 candidates that meet the specific needs of your project. We have a 100% success rate in matching candidates to projects, within days. Posting a project only takes minutes and is risk free. Post a project today.
- Website
-
https://get.clora.com/for-employers/
External link for Clora
- Industry
- Technology, Information and Internet
- Company size
- 11-50 employees
- Headquarters
- Boston, Massachusetts
- Type
- Privately Held
- Founded
- 2016
- Specialties
- Life Sciences, Pharmaceutical, Biotechnology, Medical Devices, Recruiting, Hiring, Gig Economy, Talent Marketplaces, Technology, and Marketplace Technology
Products
Life Science Talent Marketplace
Job Boards Software
Clora is a talent marketplace solving the talent crisis in the life sciences industries by enabling teams to discover, build, and manage on-demand talent.
Locations
-
Primary
200 Berkeley St
Floor 21
Boston, Massachusetts 02116, US
Employees at Clora
-
Rahul Chaturvedi
Founder/ CEO at Clora and Co-Founder of the Biotech2050 Podcast
-
Joe St.Germain
Fractional CFO& Controller - providing leadership to startups and growth oriented businesses
-
Shankar Srinivasan
Clinical Project Management Consultant | PhD, MBA
-
Rhianna Hayes
Leading Talent Acquisition Strategy @ Clora | Life Science Industry
Updates
-
The life sciences sector is experiencing a surge in M&A activities, and all signs point to this trend continuing strong in the coming years. Recent high-profile deals such as Biogen's ambitious plan to spend up to $8 billion on acquisitions this year and AbbVie's $250 million purchase of Celsius are clear indicators of this movement. The driving force is the impending patent cliff faced by big pharma and biotechs. According to an EY report, industry leaders could lose up to $350 billion in revenue between 2023 and 2028 as some of the best-selling biologics lose patent protection and start facing biosimilar competition in both the US and the EU: https://lnkd.in/et8mpQDk This looming revenue loss is compelling big pharma acquirers to pay high premiums for innovative biotech firms to bolster their pipelines and mitigate the impact of these patent cliffs. However, it's not just pharma feeling the squeeze; many established biotechs are also grappling with similar challenges and turning to M&A as a strategic response. At Clora, we understand the importance of staying ahead in this rapidly evolving landscape. Whether you're looking to reach development milestones faster with low fixed costs, bolster investor relations or licensing expertise, or manage complex integrations post-acquisition, Clora's global network of expert consultants is here to help you thrive. Send us a message to learn more. #Clora #biotech #pharma #mergersandacquisitions #innovation #patentcliff
-
Did you know that 48% of biotech roles go unfilled? To mitigate the impact on development timelines, organizations often react by either overinvesting in the wrong full time hires or overburdening teams by having to do without. These inefficiencies end up hurting development efforts in the long run. With current market conditions putting additional pressure on teams to preserve capital while quickly showing proof of concept, it is vital for organizations to rethink hiring strategies. Clora unlocks access to top-tier, on-demand consultants who can rapidly integrate into your team and bridge the gap while you search for the right full-time candidate. By leveraging our network, you can adapt to challenges while ensuring your critical work continues seamlessly. Discover how you can efficiently fill critical roles, maintain momentum, and keep programs on track in our hiring report: https://ow.ly/B9et50SuPiz #Clora #biotech #lifesciences #hiring #talentacquisition #whitepaper #hiringreport
-
-
The biotech industry is experiencing a surge in funding and focus on obesity and metabolic disorders, marking a significant shift towards addressing these pervasive health challenges. Recent investments highlight this trend, including BioAge Labs (a Clora client) securing a remarkable $170M in Series D financing to fund their lead azelaprag program and robust metabolic diseases pipeline. Metsera raised a substantial $290M Series A round to launch their next-generation injectable and oral weight loss medicines, positioning themselves as a strong contender in the obesity drug market. Big pharma is also making significant strides. Eli Lilly and Company recently announced a $5.3B investment in a new manufacturing site in Indiana, driven by soaring demand for obesity drugs. As the industry mobilizes to tackle these complex health issues, access to highly specialized expertise becomes crucial. At Clora, we empower life science companies by providing a platform that seamlessly matches them with the GLP-1 and metabolic diseases experts needed to accelerate development and bring these critical therapies to market. Send us a message to learn more. Resources: Reuters: https://ow.ly/OJ5X50SlXPM BioPharma Dive: https://ow.ly/VgLh50SlXPI Reuters: https://ow.ly/N2Zr50SlXPJ #Clora #biotech #pharma #healthcare #obesity #metabolicdisease #glp1
Eli Lilly partner BioAge raises $170 mln for obesity treatment
reuters.com
-
In recent months, we have seen a trichotomy develop in biotech among venture capital funding, bankruptcies, and M&A activities. Here are some of the notable trends: VC funding for startups has faced challenges, with investments showing a downward trend in Q1 2024. However, areas like AI-driven drug development are still attracting significant interest and investments. Bankruptcies hit a ten-year high in 2023, highlighting the sector's volatility. Several companies faced financial difficulties, leading to a spike in insolvencies. The first quarter of 2024 saw a notable increase in M&A activities within the sector, more than doubling compared to the same period last year. Big pharma companies are actively pursuing strategic acquisitions to bolster their pipelines and expand their capabilities. What has you most excited or concerned with these trends? Let us know in the comments below! Sources: Ropes & Gray LLP: https://ow.ly/ufom50Sj0je Crunchbase: https://ow.ly/R0Z050Sj0jf Fierce Biotech: https://ow.ly/w1zz50Sj0jc & https://ow.ly/QoH650Sj0jh #Clora #biotech #venturecapital #mergersandacquisitions #AI #drugdevelopment #pharma
The Mixed State Of Startup Funding In 2024, In 11 Charts
news.crunchbase.com
-
Join Rahul Chaturvedi, CEO of Clora, as he chats with Ken Keller, President and CEO of Daiichi Sankyo US, on a new episode of the Biotech2050 podcast. Ken shares insights into Daiichi’s strategic pivot to oncology, their industry-leading breakthroughs in antibody-drug conjugates (ADCs), and the success of their HER2-targeted therapies. He also discusses the power of strategic partnerships, building a passionate, impact-driven team, and his visionary perspective on the future of cancer treatments. Listen now using the link below. #Clora #podcast #biotech #oncology #leadership #cancertreatment #adcs #antibodies #HER2
In the latest episode of the Biotech2050 podcast, Ken Keller, President and CEO of Daiichi Sankyo US Sankyo, Inc., joins host Rahul Chaturvedi, Founder and CEO of Clora, to discuss how Daiichi Sankyo is transforming the oncology landscape with their groundbreaking work in antibody-drug conjugates (ADCs). Ken delves into the company's strategic shift from cardiovascular to oncology, emphasizing the success of their HER2-targeted therapies. He also explores the crucial role of strategic partnerships, the importance of building a passionate and impact-driven team, and his visionary outlook on the future of cancer treatments. Tune in for an enlightening conversation on the future of oncology and the innovative strides being made by Daiichi Sankyo. #BioTech2050 #Oncology #CancerTherapies #ADCs #BiotechInnovation #CancerResearch #StrategicPartnerships #PharmaLeadership #BiotechPodcast Listen now: https://lnkd.in/eh_FEYfz
Transformative Oncology Innovations, Ken Keller, President & CEO, Daiichi Sankyo, Inc. by Biotech2050 Podcast
soundcloud.com
-
After a challenging 2023, the biotech IPO market has seen a resurgence in early 2024 with several companies, including Alto Neuroscience, ArriVent Biopharma, and Contineum Therapeutics, successfully going public. This positive trend is essential for the industry, providing crucial funding to advance innovative therapies. However, experts caution that it remains to be seen whether this surge will continue throughout the year. The market's long-term performance will depend on broader economic conditions and investor sentiment. Read more in BioPharma Dive: https://ow.ly/I70G50Sa304 At Clora, we’re excited about these developments. Our platform is here to support emerging biotechs by connecting them with flexible, top-tier talent, ensuring they have the expertise needed to easily navigate this dynamic landscape while keeping fixed costs low. #Clora #biotech #IPO #innovation #biopharma
Biotech IPOs heated up to start 2024. Will the surge last?
biopharmadive.com
-
We're thrilled to see our client, Formation Bio, join forces with Sanofi and OpenAI in a groundbreaking collaboration. This partnership aims to leverage AI to revolutionize drug development, creating custom AI-powered solutions to bring innovative treatments to patients more efficiently. Read more in Sanofi's press release: https://ow.ly/ZHEl50S14GE This collaboration is part of a broader trend in AI and biotech, recently highlighted in the news. MIT Technology Review reports a new wave of AI-generated drugs poised to transform the pharmaceutical landscape. TIME discusses the potential for an imminent "ChatGPT moment" in biotech, where AI could revolutionize the industry. Fast Company recognizes the most innovative biotech companies of 2024, many of which are leveraging AI to push boundaries. It's clear that AI in biotech is a hot topic and gaining significant attention. We want to know - how is your organization leveraging AI? What does the future of AI in biotech hold? Comment below. Sources: MIT Technology Review: https://ow.ly/nTaE50S2qYv TIME: https://ow.ly/wPvU50S2rhy Fast Company: https://ow.ly/me3y50S2rwn #Clora #AI #biotech #pharma #innovation #drugdevelopment
Press Release: Sanofi, Formation Bio and OpenAI announce first-in-class AI collaboration
sanofi.com
-
Tune in to the latest episode of Biotech2050, where Clora CEO Rahul Chaturvedi sits down with Praveen Tipirneni, CEO of Morphic Therapeutic. Praveen shares his expertise on the current state of autoimmune therapies, Morphic's pioneering integrin discovery platform and the specific journey of Morphic’s oral α4β7 inhibitor for inflammatory bowel disease (IBD). He also talks about the importance of building strong teams and fostering a culture of excellence in biotech. Listen to their insightful discussion now using the link below. #Clora #podcast #biotech #leadership #autoimmunedisease #IBD #integrin
Excited to have Praveen Tipirneni, CEO of Morphic Therapeutic, join us on the latest episode! With a focus on developing transformative treatments for autoimmune diseases, Morphic Therapeutic is making significant strides in the biotech industry. In this episode hosted by Rahul Chaturvedi, Founder and CEO of Clora, Praveen shares insights into the current state of autoimmune therapies and Morphic's innovative approaches, including their pioneering work on oral integrin inhibitors. He also discusses his extensive experience in corporate development and strategy, highlighting the importance of building strong teams and fostering a culture of excellence. Tune in for an insightful discussion on the future of autoimmune treatment and the role of Morphic Therapeutic in shaping it! Listen now: https://lnkd.in/g6ftzSDt #Biotech #AutoimmuneTherapies #Innovation #Leadership #Healthcare #Podcast #Biotech2050
-
-
The premier event for biotech and pharma innovation is right around the corner! We're excited to attend BIO 2024 next week and connect with biotech experts and pioneers in the industry. We will be sharing how Clora is derisking drug development by modernizing hiring in our industry. Send us a message to schedule time to connect with our CEO Rahul Chaturvedi. #BIO2024 #biotech #pharma #innovation #biopharma
-